Azoulay Melissa, Shah Jennifer, Pollom Erqi, Soltys Scott G
Department of Radiation Oncology, McGill University Health Centre, Glen site, 1001 Decarie, Montreal, Quebec, H4A 3J4, Canada.
Department of Radiation Oncology, Stanford University Cancer Center, 875 Blake Wilbur Dr., Stanford, CA, 94305, USA.
Curr Oncol Rep. 2017 Sep;19(9):58. doi: 10.1007/s11912-017-0616-3.
Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM.
Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1-3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.
胶质母细胞瘤（GBM）是成人中最常见且致命的原发性脑肿瘤，尽管采用了6周放化疗的标准治疗方案，其平均生存期仍不足2年。我们回顾了有关超分割放疗（HFRT）治疗新诊断GBM的数据。
研究人员探索了替代放疗策略，这些策略缩短了治疗时间，目标是在将毒性降至最低的同时提高生存率或保持相似的生存率。对于高龄或身体状况较差的患者，1 - 3周的超分割放疗已成为标准治疗方案。对于身体状况良好的年轻患者，超分割放疗有望在放射生物学上提高剂量，并在维持生活质量的同时潜在地改善局部控制。通过使用更短的放疗分割方案并结合新型全身治疗药物，可能会改善GBM患者的治疗效果。
